Kupewa: Optimizing Strategies to Implement Provider Recommendation of HPV Vaccination for Adolescent Girls and Young Women With HIV in Malawi
Launched by NEW YORK UNIVERSITY · Jun 3, 2025
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The Kupewa clinical trial aims to find the best ways to encourage health care providers in Malawi to recommend the human papillomavirus (HPV) vaccine to adolescent girls and young women living with HIV. Researchers want to see which strategies help increase the number of recommendations for the HPV vaccine and improve the number of young women getting vaccinated. They will also look at how acceptable, practical, and cost-effective these strategies are, as well as how long their effects last. Health workers, like nurses and medical assistants, will receive training and support to help them better promote the HPV vaccine to their patients.
To be eligible for this trial, health workers must be at least 18 years old and regularly provide care at a health facility. The young women who can participate are non-pregnant females aged 9 to 24 who haven't completed their HPV vaccine series and are receiving HIV care at a facility involved in the study. If girls aged 9 to 17 are participating, their parents or guardians can also take part. Participants can expect training and support aimed at increasing vaccination rates, which could help protect against HPV-related health issues in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Health workers: People who provide medical care and counseling (typically medical assistants, clinical officers, and nurses), and interact with adolescent girls and young women aged 9-24 and/or their parents/caregivers.
- • Clients: Non-pregnant females aged 9-24 (for those aged 9-17, their male or female parent/guardian will also be eligible for participation) who have not completed the HPV vaccine series and present for HIV care at a participating health facility during the study period.
- Exclusion Criteria:
- • Health workers: Less than 18 years of age, or not an active and regular provider of medical care or counseling at the facility, or unable or unwilling to provide informed consent
- • Clients: \<9 or \>24 years old, or pregnancy, or completed HPV vaccine series prior to study, or unable or unwilling to provide informed consent
About New York University
New York University (NYU) is a prestigious research institution renowned for its commitment to advancing medical knowledge and improving patient care through innovative clinical trials. With a robust infrastructure and a diverse team of leading experts, NYU conducts cutting-edge research across various therapeutic areas, focusing on translating scientific discoveries into effective treatments. The university fosters collaboration among multidisciplinary teams and engages with a broad patient population, ensuring that its trials adhere to the highest ethical standards and regulatory requirements. NYU's dedication to excellence in research and education positions it as a key contributor to the advancement of healthcare and clinical practice.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lilongwe, , Malawi
Patients applied
Trial Officials
Corrina Moucheraud
Principal Investigator
New York University
Risa M Hoffman
Principal Investigator
University of California, Los Angeles
Sam Phiri
Principal Investigator
Partners in Hope, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported